Dongfang Liu - 17 Apr 2026 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: NUVB
Reported as of: 17 Apr 2026
Net transaction value: -$251,000
SEC form: 4
Accepted by SEC: 21 Apr 2026, 16:34:07 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Dang, Attorney-in-Fact

Key filing fact

Dongfang Liu filed Form 4 for Nuvation Bio Inc. (NUVB) on 21 Apr 2026.

Key facts

This page summarizes Dongfang Liu's Form 4 filing for Nuvation Bio Inc. (NUVB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Apr 2026, 16:34.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$251,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001937915 Primary reporting owner

Liu Dongfang

Relationship: CHIEF MEDICAL OFFICER
Address: C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK
Signature: /s/ Stephen Dang, Attorney-in-Fact
Signature date: 21 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVB transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +278%
Price: $1.94^*
Shares after: 68,000
Date: 17 Apr 2026
Ownership: Direct

NUVB transaction

Class A Common Stock

Sale

Transaction value: $251,000
Shares: -50,000
Change %: -74%
Price: $5.02
Shares after: 18,000
Date: 17 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -50,000
Change %: -10%
Price: $0.000000^*
Shares after: 430,000
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 50,000
Exercise price: $1.94
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.

Footnote F2

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.07. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Option vests as to 25% on February 28, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date